Cargando…

Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants

Oncolytic viruses (OVs) can eradicate tumor cells and elicit antitumor immunity. VSV-GP, a chimeric vesicular stomatitis virus (VSV) with the glycoprotein (GP) of the lymphocytic choriomeningitis virus, is a promising new OV candidate. However, the interaction of VSV-GP with host immune cells is not...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pipperger, Lisa, Riepler, Lydia, Kimpel, Janine, Siller, Anita, Stoitzner, Patrizia, Bánki, Zoltán, von Laer, Dorothee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409795/ https://www.ncbi.nlm.nih.gov/pubmed/34484872 http://dx.doi.org/10.1080/2162402X.2021.1959140

Ejemplares similares

Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
por: Koske, Iris, et al.
Publicado: (2019)

Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum
por: Pipperger, Lisa, et al.
Publicado: (2019)

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
por: Kimpel, Janine, et al.
Publicado: (2018)

Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy
por: Muik, Alexander, et al.
Publicado: (2012)

The Methyltransferase Region of Vesicular Stomatitis Virus L Polymerase Is a Target Site for Functional Intramolecular Insertion
por: Heilmann, Emmanuel, et al.
Publicado: (2019)

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
por: Rössler, Annika, et al.
Publicado: (2022)

Comparison of Four SARS-CoV-2 Neutralization Assays
por: Riepler, Lydia, et al.
Publicado: (2020)

Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl
por: Borena, Wegene, et al.
Publicado: (2021)

Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay
por: Borena, Wegene, et al.
Publicado: (2021)

Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy
por: Simovic, Boris, et al.
Publicado: (2015)

Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
por: Hastie, Eric, et al.
Publicado: (2016)

Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector
por: Bresk, C. Anika, et al.
Publicado: (2019)

Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses
por: Clausen, Björn E., et al.
Publicado: (2015)

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial
por: Bánki, Zoltán, et al.
Publicado: (2022)

Marked Increase in Avidity of SARS-CoV-2 Antibodies 7–8 Months After Infection Is Not Diminished in Old Age
por: Pichler, Daniel, et al.
Publicado: (2021)

Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer
por: Heiber, Joshua F., et al.
Publicado: (2011)

Oncolytic vesicular stomatitis virus expressing interferon-γ has enhanced therapeutic activity
por: Bourgeois-Daigneault, Marie-Claude, et al.
Publicado: (2016)

Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers
por: Nagalo, Bolni Marius, et al.
Publicado: (2020)

Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells
por: Kim, Teddy E., et al.
Publicado: (2021)

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
por: Dold, Catherine, et al.
Publicado: (2016)

RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization
por: Wilmschen, Sarah, et al.
Publicado: (2019)

Experimental Evolution of an Oncolytic Vesicular Stomatitis Virus with Increased Selectivity for p53-Deficient Cells
por: Garijo, Raquel, et al.
Publicado: (2014)

N-Myc expression enhances the oncolytic effects of vesicular stomatitis virus in human neuroblastoma cells
por: Corredor, Juan C, et al.
Publicado: (2016)

Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil”
por: Melzer, Michael Karl, et al.
Publicado: (2017)

SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
por: Alkayyal, Almohanad A., et al.
Publicado: (2023)

Hydrodynamic characterization of a vesicular stomatitis virus-based oncolytic virus using analytical ultracentrifugation
por: Wawra, Simon, et al.
Publicado: (2023)

Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells
por: Goad, Dakota W., et al.
Publicado: (2023)

High SARS-CoV-2 seroprevalence in children and adults in the Austrian ski resort of Ischgl
por: Knabl, Ludwig, et al.
Publicado: (2021)

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria
por: Bánki, Zoltán, et al.
Publicado: (2022)

Potent systemic therapy of Multiple Myeloma utilizing Oncolytic Vesicular stomatitis virus coding for Interferon-beta
por: Naik, Shruthi, et al.
Publicado: (2012)

Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models
por: Le Boeuf, Fabrice, et al.
Publicado: (2017)

In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
por: Jenner, Adrianne L, et al.
Publicado: (2021)

Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions
por: Holbrook, Molly C., et al.
Publicado: (2021)

Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus
por: Goad, Dakota W., et al.
Publicado: (2021)

Aphthæ, or Vesicular Stomatitis of the Horse
por: Hutcheon, D.
Publicado: (1898)

Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines
por: Bridle, Byram W, et al.
Publicado: (2013)

Generation of a Tumor-Specific Chemokine Gradient Using Oncolytic Vesicular Stomatitis Virus Encoding CXCL9
por: Eckert, Elizabeth C., et al.
Publicado: (2019)

Correction: In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
Publicado: (2021)

Intravesical immunotherapy with a GM-CSF armed oncolytic vesicular stomatitis virus improves outcome in bladder cancer
por: Rangsitratkul, Coby, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_slt2plrj9o1m5vipfi28u8qjkl